@CIR_AACR Highlights from LR deep dive into TIGIT &amp; PVRIG including upcoming catalysts, the efficacy bar that Roche's tiragolumab data need to beat in #NSCLC and clinical data for the class to date.

$RHHBY $MRK $BMY $ALPMY $RCUS $CGEN $BGNE $SGEN $IVBXF $MREO @iTeosTx https://t.co/6CATrxkH6D